NEW INSIGHTS ON INHIBITOR DEVELOPMENT:IMPLICATIONS IN PUP MANAGEMENT

MONDAY 25 JULY, 2016 12:30 - 14:00Lunch box provided

Room 308 • West Building, level 3Orange County Convention Center 9400 Universal Blvd, Orlando, FL, USA

In conjunction with the XXXIInd congress of the World Federation of Hemophilia July 24-28, 2016, Orlando, USA

SYMPO

SIUM

Welcome to Orlando Louis Aledort, New York, USA

What is known today on mechanisms for inhibitor development Sébastien Lacroix-Desmazes, Paris, France

What can be learned from national registries and published data Jenny Goudemand, Lille, France

Results from a randomized controlled trial on inhibitor development in PUPs: the SIPPET study Flora Peyvandi, Milan, Italy

The pharmacoeconomical perspective: Inhibitor costs Lorenzo Giovanni Mantovani, Monza, Italy

Discussion

Round table on how recent findings can impact on PUPs management Chairs: Louis Aledort and Guy Young Patients organization perspective: Doctors’ perspective: Carmen Escuriola-Ettingshausen, Frankfurt - Mörfelden, Germany Robert Sidonio, Atlanta, USA

12:45 •13:00

13:00 •13:15

Chairs:

Louis ALEDORT Mount Sinai School of Medicine, New York, NY, USA

Guy YOUNG Children’s Hospital and University of Southern California Keck School of Medicine, Los Angeles, CA, USA

- EV

E-01

305-

3/20

16.

12:30 •12:35

12:35 •12:45

13:25 •13:30

13:30 •14:00

13:15 •13:25

NEW INSIGHTS ON INHIBITOR DEVELOPMENT: IMPLICATIONS IN PUP MANAGEMENT

PROGRAM